Opinion
Video
Overcoming DLBCL Treatment Hurdles
Experts discuss limitations and operational strategies for integrating bispecifics in diffuse large B-cell lymphoma (DLBCL) treatment; addressing adverse effects, education, clinical pathways, and collaboration for effective patient care.
This is a video synopsis/summary of a Practice Pearls involving Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA; Robert Mancini, PharmD; and Amir Ali, PharmD, BCOP, FHOPA.
In this segment, Mahmoudjafari and Ali discuss challenges and limitations of bispecific therapies in lymphoma. Ali emphasizes the significant limitation of adverse effects, hindering adoption in smaller community oncology centers. Mancini highlights operational considerations, emphasizing the need for adaptable treatment settings and collaboration with hospitals. He underscores the importance of extensive education for patients, caregivers, and health care professionals, extending to ancillary and emergency staff.
The conversation addresses the revision of pathways to accommodate the evolving treatment landscape and the individualized nature of care in lymphomas. Ali raises questions about the timing and sequencing of therapies, particularly the use of bispecifics before or after chimeric antigen receptor T-cell therapy in DLBCL patients, emphasizing the ongoing need for answers as pathways evolve. The discussion highlights the complex considerations in implementing bispecific therapies and the ongoing efforts to address challenges and improve patient care.
This summary was AI-generated and reviewed by Pharmacy Times® editorial staff.
